1 in 8 couples in the U.S of childbearing age has trouble conceiving or sustaining a pregnancy.

According to the American Society of Reproductive Medicine, endometriosis is the likely cause of 30-50% of all cases of unexplained infertility.

Studies have also shown that even the mildest forms of endometriosis can affect your ability to conceive and maintain a successful pregnancy.

Until now, endometriosis could only be detected through invasive laparoscopy.

But we’ve got great news that is already having a positive impact in reproductive medicine.

ReceptivaDxTM represents one of the most powerful tools available for understanding unexplained infertility. Based on a simple endometrial biopsy sample, ReceptivaDx provides patients and their healthcare providers an assessment of uterine receptivity and the unique ability to identify previously undetected endometriosis. This incredible new information can then lead to targeted treatments to help resolve previously unexplained infertility.

Subscribe to our newsletter and stay up to date with ReceptivaDx.
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
© 2017 Receptivadx. All Rights Reserved